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ABSTRACT
Introduction :  Economic evaluations can provide “value-for money” information to those making 
decisions about the allocation of limited health care resources. In particular, economic 
evaluations can be used to identify interventions that are worth providing and those that 
are not. Furthermore, evaluations can be used with other approaches to help set priorities, 
such as program-budgeting marginal-analysis. 
Methodology : Compile and systematically describe from the publications, articles and reports on 
economic evaluation in healthcare decision making .
Result            :    A high quality economic evaluation should provide decision makers with information that 
is useful, relevant, and timely. In addition, evaluations should be based on rigorous 
analytical methods, be balanced and impartial (credible), and be transparent and 
accessible to the reader. There are many situations where economic evaluations can assist 
decision makers: decisions by various levels of government or administrative bodies (e.g., 
regional health authorities, hospitals, drug plans) to fund a program, service or 
technology, pricing decisions by government regulators and technology manufacturers, 
clinical practice guidelines, priorities for research funding by governments and research-
based firms,  post-marketing surveillance and updates of economic information based on 
the use of the technology in the “real world” (which can then be used to inform one of the 
other types of decisions).
  :   This requires that decision makers take a broad view of the impact of a technology, and  
decision that are more explicit and transparent. The ultimate test of an evaluation is 
whether it leads to better decision in the presence of uncertainty, and results in the more 
efficient and effective use of resources. 
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INTRODUCTION
Economic considerations have assumed an 
increasingly prominent role in the planning, 
decision making, management and evaluation of 
health systems, ranging from the design of ways 
to pay providers or to improve access to care for 
households, to the definition of essential 
packages for insurance, to decisions about 
whether or not to include new medicines on 
hospital, state or national formularies.
Increased attention to issues of cost 
and efficiency have been prompted by the 
pervasive scarcity of resources relative to health 
needs and demands, driven by factors such as the 
HIV pandemic, ageing populations, the 
development of innovative but often expensive 
technologies and also by the heightened 
knowledge and expectations of healthcare 
consumers1. These classical forces of supply and 
demand on the market for healthcare have given 
rise to the need for sophisticated methods of 
quantitative analysis, including modeling of 
disease processes and outcomes, econometric 
modeling for population-based resource 
allocation exercises, macro-level modeling of the 
impact of (ill-) health on wealth (and vice versa), 
and multi-state decision analytic models that 
assess the technical efficiency of health 
interventions.
As part of this process, economic 
evaluation has become a commonly used tool to 
inform health policy as well as to guide clinical 
decisions1. It establishes the relative costs and 
impacts of health interventions, with the 
underlying objective of maximizing population 
health for the available resources. There are now 
many thousands of completed evaluations that 
have identified how and where efficiency 
improvements could be made. Many are clinical 
and most focus on ways to address a particular 
disease or health problem, but a few have 
considered how the efficiency of the health 
sector as a whole could be improved2.
In some countries, the use of cost-
effectiveness analysis has been institutionalized 
for decision making, most commonly to address 
the question of public subsidies for the purchase 
of medicines. In other settings, the influence of 
this accumulated body of economic evidence on 
decision making and resource allocation is 
harder to detect. In part, this is due to the fact 
that it can be difficult to attribute changes in 
policy or resource allocation to the presence of 
an economic evidence base when economic 
evidence is but one of the factors that is typically 
considered when households, firms or 
governments make such decisions. However, it is 
also the case that decision makers find the 
evidence difficult to interpret and apply because 
of methodological heterogeneity and 
inconsistency, which limits the comparability 
and generalisability of different results. This 
policy review takes a step back and looks 
objectively at the role and use of cost-
effectiveness analysis at the population level 
within the broader context of health system 
financing, commenting in particular on the extent 
to which it can be used to address key financing 
challenges.
2.0 Economic Evaluation
2.1Economic Framework
In principle the objective of economics is to 
maximize social wellbeing or welfare when the 
resources that are available are limited3. The 
distinctively economic contribution to this task 
arises from recognition that, when resources are 
scarce, their use to achieve one objective 
necessarily prevents their use for some other 
purpose. This gives rise to the most fundamental 
and important concept in economics; vis the 
concept of an opportunity cost which is defined 
as the value of the benefits that are foregone 
(opportunities lost elsewhere) because of the use 
of resources to achieve a particular objective. 
This is shown in Figure 1. 
                        VS
Figure 1 Simplified Economic Framework 
        (adapted from Richardson 1999)
At the level of abstraction embodied in 
Figure 1 the conclusion that costs and benefits 
should be compared for maximum wellbeing is a 
necessary truth as anything which adds or 
subtracts from wellbeing is included in the 
framework. Controversy only arises when these 
broad concepts are operationalised. In the 
practice of economic evaluation, the first step is 
to distinguish ethical distributional and other 
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intangible benefits from those which are more 
readily measured; vis, those that are associated 
with the use of real resources. In Figure 2 where 
this distinction is illustrated, narrowly defined 
economic evaluation is often associated with the 
left hand side of the figure which deals with 
‘economic costs and benefits’. In principle, the 
distinction shown in this figure is artificial. 
Anything contributing to social welfare could be 
included in an analysis. In practice, this broad 
objective is difficult to achieve, firstly, because 
ethical and intangible considerations are often 
difficult to quantify but more fundamentally 
because there is often disagreement about which 
ethical values should be incorporated in an 
analysis and, in particular, it is unclear how 
benefits to different individuals should be 
combined to determine ‘social welfare’. For this 
reason, good economic evaluation will simply 
note effects that are relevant to issues of social 
justice, equity and distribution. This does not 
always occur in practice. Many economic 
analyses are concerned with costs and benefits 
where there are no particular ethical issues –
there is ‘distributive’ neutrality. In the domain of 
health – where compensation for loss is difficult, 
impractical or impossible – these issues, 
however, become of particular significance.
Economics deals with the exchange 
between people and the trade-offs that they make. 
In publicly funded health care systems, limited 
resources mean that every available intervention 
cannot be provided in every situation for all who 
need or want it. Choices must be made among 
effective health care interventions, and the 
decision to fund one means that others cannot be 
funded. The opportunity cost of funding the 
chosen intervention can be seen as the health 
benefits that could have been derived from 
funding the next best alternative.
Furthermore, the choice of the best 
course of action depends on weighing only the 
“incremental changes” in costs and consequences 
between the alternatives being compared. 
Consequently, it is unnecessary to weigh the full 
range of possible costs and consequences of each 
alternative.
Figure 2 Structure of Economic Evaluation (Adapted from Richardson 1999)
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2.2 What is Economic Evaluation?
Simply measuring the costs of an intervention 
will not tell us whether it is cost effective. A 
cheap intervention may represent poor value for 
money if it has little effect on outcome. 
Economic evaluation is the process of measuring 
cost effectiveness. An economic evaluation will 
measure two parameters—cost and outcome 
(effect). Because two parameters are measured, 
the results of an economic evaluation will not 
necessarily tell you which treatment option is 
“better” in the same way that a clinical trial 
might. If the cheapest option is also the most 
effective, it will clearly be the most cost effective. 
In this situation the most cost effective option is 
described as being dominant. However, if the 
cheapest option is not the most effective the 
decision of which intervention to choose is less 
clear. In this situation the results will typically 
take the form of an incremental cost 
effectiveness ratio, expressed as the additional 
cost incurred per additional unit of effect accrued. 
When no intervention is dominant economic 
evaluation will tell you how much extra you will 
need to be prepared to pay to achieve an 
improved outcome. As such, health economics 
will inform decision making, rather than
dictating a decision. The idea that economic 
evaluation is only about determining which is the 
cheapest option is a simplistic and mistaken idea. 
It is also a dangerous one as it risks losing the 
valuable insights that economics can provide4.
2.2.1 Opportunity Cost
The concept of opportunity cost is fundamental 
to economic evaluation. It is based upon the idea 
that scarcity of resources means that expending 
resources on one health care activity inevitably 
means sacrificing activity somewhere else. The 
opportunity cost of undertaking an activity is 
defined as the benefits that must be foregone by 
not allocating resources to the next best activity. 
For example, you decide to employ a chest pain 
nurse in your department to achieve National 
Service Framework targets for thrombolysis. To 
do this you must make tough choices elsewhere. 
Perhaps you must do without some clinical 
assistant sessions? But this will cause overall 
waiting times to increase. The opportunity cost 
of employing a chest pain nurse is the benefit 
you must forego by being unable to fund the next 
highest option on your list of priorities. If your 
next highest priority is more clinical assistant 
sessions, then the cost of foregoing these (an 
increase in waiting times) will be the opportunity 
cost of employing a chest pain nurse5.
2.2.2 Economic Efficiency
We often talk about trying to make the most 
efficient use of our available resources. 
Achieving economic efficiency entails obtaining 
maximum benefit from our given resources. 
There are two types of economic efficiency—
technical efficiency and allocative efficiency.
Technical efficiency simply entails 
achieving a given objective with the least 
possible expenditure. If our objective is to reduce 
A&E waiting times, we could achieve this by 
employing more medical staff or by training 
nurse practitioners to assess and treat patients 
with specific complaints. The most technically 
efficient option will be that which reduces 
waiting times at the lowest cost. We are simply 
concerned with how we meet our specified 
objective—reducing waiting times.
Allocative efficiency entails deciding 
what objectives we will attempt to meet and the 
extent to which we will try to meet them. 
Determining allocative efficiency entails making 
a value judgment about the relative merits of 
different objectives. The example given earlier, 
where we had to decide whether to allocate 
resources to employ a chest pain nurse to achieve 
door to needle time targets for thrombolysis, or 
employ clinical assistants to reduce overall 
waiting times, is an example of a decision 
relating to allocative efficiency. It is not simply a 
matter of deciding which intervention will best 
meet our objective, we must decide which 
objective is most worthwhile meeting. Questions 
of technical efficiency are unsurprisingly rather 
easier to answer than those relating to allocative 
efficiency. Economic evaluation may be used to 
inform and illuminate issues of allocative 
efficiency, but because a value judgement is 
required, decision making will ultimately be up 
to clinicians, patients, politicians, and health care 
managers. Health economic data may tell us how 
much we will need to pay to achieve our 
objectives—reducing door to needle times and 
reducing overall waiting times. Health economic 
data can also tell us what health benefits we 
might expect from achieving certain targets, such 
as how many lives will be saved by reducing 
door to needle time by a specific amount. More 
controversially, comparisons between 
interventions, such as those presented in a 
“marginal cost per QALY league table”, can 
address some of the issues of allocative 
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efficiency. Ultimately, however, deciding which 
benefits are worthwhile will entail some sort of 
value judgement.
2.2.3 The key features of an economic 
evaluation
An economic evaluation is a comparison of the 
costs and outcomes of health care interventions6. 
As such it provides a measurement of economic 
efficiency. To be an economic evaluation a study 
must have two essential features:
(1) Both costs and outcomes must be 
analysed, and
(2) More than one alternative strategy 
must be compared.
It should be clear by now that economic 
evaluation is not simply a matter of measuring 
costs of interventions and then choosing the 
cheapest option. This is clearly foolish and not 
an approach any of us would take in our lives 
outside health care. If you wanted to buy a 
product you wouldn’t simply buy the cheapest 
available regardless of quality, your personal 
preference, or whether it did what it was 
supposed to do. Equally, we do not always buy 
the best product available as we wish to have 
money left to buy food7. Cost is important, but 
no more important than the outcome from the 
expenditure. It may ultimately be appropriate to 
choose on the basis of cost alone, but only if we 
can show that outcomes are equivalent. 
Measuring outcome from health care 
interventions is one of the great challenges of 
health economics. It is astonishing, considering 
the amount of money we spend on health care, 
that our ability to measure benefit from health 
care is only recently receiving serious attention, 
and remains relatively crude. We collect reams 
of data showing how many new patients attend 
our department, how many investigations we do, 
and how many treatments we do. Yet is any of 
this of any benefit to our patients? Just as we 
would not accept evidence of effectiveness 
without comparison to a control group, we 
cannot measure cost effectiveness without some 
sort of comparison. The choice of comparator 
may be difficult, because we want to choose the 
best alternative from the point of view of both 
costs and benefits. For this reason, if there is no 
alternative strategy that is of proven 
effectiveness, the most appropriate comparator 
may well be a “do nothing” alternative. Doing 
nothing certainly should not cost much, and, if 
there is no evidence that the intervention being 
investigated is effective, will be relatively cost 
effective
2.3 Timing of evaluations
Economic evaluations can be undertaken at any 
point in the life cycle of a technology. The 
timing of a study ultimately depends on the 
needs of the decision makers. If an evaluation is 
conducted late in the life cycle, there is a risk 
that the findings will not be of use to the decision 
maker, because the funding decision has been 
made, or the intervention has diffused into 
clinical practice, though the findings could 
inform decisions about changes to 
reimbursement status or the intended target 
population. If a technology is evaluated early in 
its life cycle, before evidence on its effectiveness 
is clear, there is a risk that the uncertainty about 
the costs and effects would be larger than if it is 
evaluated later. Often, the effectiveness of 
technologies depends on the setting, and 
sometimes on the operator’s experience if there 
is a learning curve associated with it. Performing 
evaluations is an iterative process7.
A well conducted evaluation will 
identify the most important sources of 
uncertainty, and thereby will direct the gathering 
of evidence to those areas. This produces more 
accurate estimates of an intervention in the long 
term. 
3.0 Types of Economic  Evaluation
Several types of economic evaluation are 
recognized. It is the measurement of outcome 
that determines what type of economic 
evaluation has been performed.
3.1 Cost Minimization Analysis
If the outcomes of the alternative strategies are 
demonstrated to be equivalent, then analysis will 
consist of simply comparing costs and choosing 
the cheapest option. Demonstration of 
equivalence of outcome may entail presentation 
of primary data from the study itself, or 
presentation of secondary data, such as the 
results of a meta-analysis. While this sounds 
simple, cost minimization analyses often 
conveniently ignore the issue of uncertainty 
surrounding the estimates of comparative 
effectiveness. Outcomes are extremely unlikely 
to be identical. More probably there is no 
statistically significant difference in outcome. 
All good clinical trials, and meta-analyses, 
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should present their results with confidence 
intervals. These will probably include the 
possibility of the more costly option also being 
more effective. Estimating confidence intervals 
for cost effectiveness data is difficult and well 
beyond the scope of this article. However, it is 
always worth examining the confidence intervals 
for outcome data presented with a cost 
minimization analysis to see whether the more 
expensive strategy could still produce a 
worthwhile improvement in outcome.
3.2 Cost Effectiveness Analysis
For a cost effectiveness analysis, the outcomes of 
the alternative strategies are not equivalent and 
are measured in uni-directional natural units, 
such as lives saved, change in pain score, or 
change in peak flow rate. The results are 
therefore helpful in determining technical 
efficiency. They tell us which strategy 
maximizes a given objective, such as improving 
pain score, with the lowest cost. An example of a 
cost effectiveness analysis might be a 
randomized controlled trial comparing the costs 
and effects of two thrombolytic agents for acute 
myocardial infarction. A suitable primary 
outcome might be mortality at 30 days. If the 
cheaper thrombolytic agent were also the most 
effective, interpretation of the results would be 
easy and our choice of thrombolytic therapy 
clear. The cheaper, more effective agent would 
be dominant. But what do we do if the more 
expensive agent is also the most effective? If we 
make our decision on the basis of cost we will 
choose the cheapest agent, whereas if we make 
our decision on the basis of effectiveness, we 
will choose the more expensive agent. The study 
can help our decision making by presenting 
results as a cost effectiveness ratio. This tells us 
how much extra we must pay for each additional 
life saved and allows us to consider whether 
alternative uses of the same resources would 
generate more health benefits. So how much 
should we be prepared to pay to save a life at 30 
days with our more expensive thrombolytic 
agent? £10 000? £100 000? How about £1 
million? This is, of course, a value judgement 
and depends upon many factors. Again it is 
worth emphasising that economic evaluation can 
inform and illuminate the decision making 
process, but cannot make the decision for us. 
Deciding whether to fund this expensive 
thrombolytic agent, it would clearly be useful to 
be able to compare our cost effectiveness ratio to 
estimates of cost effectiveness for other 
competing uses for our resources. Yet many 
interventions in A&E (or health care in general) 
will not affect mortality. How do we compare 
our cost per life saved to the cost per change in 
pain score of an expensive analgesic agent, or the 
cost per change in peak flow rate of a treatment 
for asthma? This is an important limitation of 
cost effectiveness analysis.
3.3 Cost Utility Analysis
For a cost utility analysis the outcomes of health 
care interventions are measured in units of health 
outcome that combine quality and quantity of 
life, and can thus be compared between different 
interventions and health problems.The most well 
known example of a measure of health utility is 
the quality adjusted life year, or QALY. 
Calculation of QALYs entails first measuring 
quality of life on a scale from zero to one, where 
zero equates to death and one equates to perfect 
health. The period of time (in years) over which 
this quality assessment applies is then multiplied 
by its quality weighting to give the number of 
quality adjusted life years. Cost utility analysis 
therefore offers the attractive prospect of 
allowing comparison of a wide and varied range 
of health care interventions. This has lead to the 
development of “marginal cost per QALY league 
tables”, which compare the marginal cost per 
QALY of interventions as diverse as cholesterol 
screening and heart transplantation. There are 
many theoretical, methodological, and ethical 
concerns with these analyses that are beyond the 
scope of this article. Well conducted cost utility 
analyses comparing interventions within the 
same area of health care can be a powerful way 
of assisting decision making, but the use of 
marginal cost per QALY league tables to 
compare diverse health care interventions is 
highly controversial8.
3.4 Cost-Benefit Analysis
Although the expression “cost-benefit” analysis 
is commonly used for any form of economic 
analysis, it has a very specific meaning in health 
economics. It refers to economic analyses in 
which the outcomes are valued in monetary units. 
As costs and benefits are both measured in the 
same units they can be compared directly. This is 
clearly very useful for assisting decision making. 
However, measuring benefits in monetary units 
presents substantial difficulties. While cost-
benefit analyses have many theoretical 
attractions for health economists, they are 
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unlikely to be frequently encountered in the 
medical literature.
3.5 Cost Consequence Analysis
This is a form of cost effectiveness analysis. 
Ideally a cost effectiveness analysis will have a 
primary outcome that can be used to produce a 
cost effectiveness ratio. However, often more 
than one outcome is relevant and it is difficult to 
determine which is the most important. For 
example, a trial comparing the cost effectiveness 
of treatment for sprained ankle might consider 
ability to weight bear, pain score or several other 
outcomes to be equally important. Combining 
several outcomes to create a single index of 
health utility is one option, but this may be 
insensitive to important differences in outcome. 
Another option is to present a cost consequences 
analysis. All important outcomes are presented 
with relevant cost effectiveness ratios and the 
reader is left to judge the relative importance of 
the outcomes9. The limitation of this type of 
analysis is that it does not allow transparent 
assessment of whether the health gained from the 
expenditure of limited resources is being 
maximised. A decision maker can only be 
confident of this when one intervention 
dominates the others on all outcomes and cost.
Table 1   Strengths and limitation economic evaluations
NAME MEASUREMENT 
UNIT FOR EFFECTS
STRENGTHS LIMITATIONS
Cost benefit analysis 
(CBA)
All effects measured in 
dollars.
The net benefit (NB) is easy 
to interpret. For example, a 
new treatment’s extra 
benefits are worth more than 
the extra costs when NB > 
0.
It is difficult to measure the value of 
all health outcomes in dollars.
There may be moral objections about 
the impact of ability to pay in the 
process of valuing the effects.
Cost–utility analysis 
(CUA)
Two effects (quality and 
length of life) whose 
product is taken as 
quality-adjusted life years 
(QALYs).
Patient outcomes involving 
both quality and length of 
life can be incorporated in 
the analysis.
In theory, the QALY 
measure is “universal,” so 
that very different programs 
evaluated with QALYs can 
be compared.
QALY measures vary by method.
QALY measures vary by 
respondent.
Society may value a QALY for 
different patient groups differently 
(for example, is a QALY gained for 
sufferers of erectile dysfunction 
valued the same as a QALY gained 
for sufferers of severe mental 
illness?)
Cost-effectiveness 
analysis (CEA)
One effect measured in 
“natural units”.
There is one outcome and it 
is measured in its “natural 
units.”
Only one outcome will represent the 
effect of treatment; however, other 
outcomes may be relevant.
Cost-minimization 
analysis (CMA)
No effects measured. There is only a need to 
collect cost data.
Few treatments have identical 
outcomes.
Researchers would likely need to 
collect the effect data to verify the 
“equal effect” 
assumption
Robinson(1993)
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4. Economic evaluation studies
4.1 Economic evaluation of two regional 
palliative care programs for terminally I11 
cancer patient
One in three Canadians is diagnosed with cancer 
at some point in his or her life, and about half of 
those people die of the disease. A review of the 
literature reveals there is a lack of large-scale, 
comparative studies of palliative care 
innovations — the net result of which is a small 
evidence base upon which decision makers can 
rely6. 
The objective of that study was to 
describe, explain and evaluate the economic 
consequences of introducing two comprehensive, 
co-ordinated and integrated palliative care 
programs in two large urban centers in Alberta, 
Canada. 
In the area of program management, it 
is important that new services and initiatives —
including shared-care models with other 
healthcare teams — be implemented that further 
enhance access, co-ordination, quality of care, 
and appropriate use of resources. Furthermore, 
resources for residential hospice and homecare 
should be increased to allow patients to move out 
of acute care sooner, and decision makers should 
co-ordinate with the existing community and 
volunteer resources that already provide end-of-
life care for palliative patients. 
4.2 Economic evaluation in dentistry
“When alternative therapies are available, 
patients want the choice of treatment to be based 
on processes that are cost-effective and have 
proven outcomes”10. 
It is likely there will be an increased 
demand for economic analyses of dental 
interventions by the public and by those funding 
healthcare and the National Institute for Clinical 
Excellence (NICE) may play an important role in 
this area in the future. Both the NHS and private 
companies are likely to demand increased 
evidence of value for money in the future. This is 
particularly important in areas which may be 
perceived as 'cosmetic'.
Economic evaluation is still used less 
frequently in dentistry than in medicine. 
However, this is beginning to change. A recent 
computerised literature search showed the 
following; 'Cost effectiveness and dentistry' 
produced 388 papers published between 1971 
and 1999 with 67of those in 1997/98 ;Cost 
benefit and dentistry' produced a total of 370 
papers published between 1971 and 1999 with 
66 of those in 1997/98 ;'Cost utility and 
dentistry' produced only 18 papers, all of which 
were published between 1980 and 1998 with 5 of 
those in 1997/98 and cost minimisation and 
dentistry' produced no papers at all. 
It is, however, worth noting that a 
number of papers were listed under both cost 
benefit and cost effectiveness. This stresses the 
importance that papers must be read carefully to 
determine which method of analysis was actually 
used. It is also worth noting that a large number 
of the papers which were listed, had not 
undertaken any form of economic analysis and 
merely mentioned that economic evaluation 
would be a useful next step in research. A 
relatively small number of the papers had 
undertaken carefully controlled economic 
evaluation.
Cost effectiveness and cost benefit 
studies are therefore carried out much more 
frequently than cost utility studies, which 
probably reflect the increased difficulty and time 
consuming nature of cost utility type studies. 
However, the cost utility method would be 
particularly useful in the field of dentistry 
because treatments frequently produce 
improvements in quality of life. In addition, 
QALY based investigations in dentistry would 
also allow some method of comparing dental 
interventions with other forms of medicine.
Cost effectiveness and cost benefit 
studies have focused largely on comparison of 
restorative materials and cost implications of 
fluoride, fissure sealants and caries prevention11. 
Recent years have also seen a number of papers 
undertaking economic analysis of implants. 
The following examples of economic 
evaluation in dentistry have been selected to 
illustrate the issues described in the previous 
sections. It is not intended to be an exhaustive 
list, good example of clinical trials and economic 
evaluation being undertaken concurrently is that 
by Severens et al.(1998) who assessed the short-
term cost effectiveness of pre-surgical 
orthopaedics in babies with a complete unilateral 
cleft of the lip and palate. There was a significant 
difference in both medical and indirect costs for 
the two groups with the pre-surgical orthopaedic 
group being higher. However, there was no 
significant difference in outcome (which was 
assessed in terms of operating time) between the 
two groups. Thus concluding that pre-surgical 
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orthopaedics was not cost-effective in terms of 
reduced operating time12. Obviously, other 
important outcome measures such as appearance 
and function must be assessed but these were not 
reported in this paper.
Klock(2000) looked at CBA(Cost 
Benefit Analysis) and CEA(Cost Effectiveness 
Analysis) of a preventive programme (including 
oral hygiene, fluoride application and fissure 
sealants) and found that in spite of a reduction in 
caries activity, the programme was uneconomic 
compared with traditional dental care. In contrast, 
Morgan et al. assessed the cost-effectiveness of a 
preventive programme in two non-fluoridated 
regions of Australia and concluded that the 
introduction of a preventive programme was an 
efficient use of resources13. 
A number of cost-effectiveness studies 
in dentistry have looked at different restorative 
materials. Mjor studied the cost-effectiveness of 
restorative materials for two and three surface 
restorations undertaken in Norway and found 
amalgam to be the most cost-effective, followed 
by composite and then gold14. A similar analysis 
of cost-effectiveness in the UK also found 
amalgam to be the most cost-effective material. 
It was proposed that the cost-effectiveness of 
composites in particular was lower due to the 
shorter longevity and the higher cost of these 
restorations8. A recent paper reported a 
systematic review of intra-coronal dental 
restorations in terms of their longevity and cost-
effectiveness. It was noted that of the 30 
economic studies identified, the majority were 
generally of poor quality, and the paper called 
for improved research in this area.
There are relatively few cost-utility 
studies in the field of dentistry. A study in 1992 
by Fyffe and Kay assessed the average utility 
values for four different 'tooth states' which it 
was hypothesised would have different values15. 
They found that the highest mean utility values 
were for the restored tooth and lowest values for 
the decayed and painful posterior tooth. Values 
were obtained from both dentists and members 
of the general public and, perhaps not 
surprisingly, dentists gave higher utility values 
when compared with members of the general 
public. Downer and Moles also studied the 
influence of relevant factors on health gain from 
restorative treatment. O'Brien et al. undertook 
the only example which was found of utility 
analysis in orthodontics. They developed a TTO 
scale questionnaire using the aesthetic 
component of the Index of Treatment Need and 
found that patients seeking treatment gave lower 
utility values than those not wanting treatment. 
However, with the visual analogue scale there 
was no significant difference. It was proposed 
that this method could also be used as a method 
for predicting patient compliance.
In the field of oral medicine/oral 
pathology, Downer et al. used the Standard 
Gamble method to elicit the public's perceptions 
of different oral cancer states - precancer, small 
cancer and large cancer and found utility values 
of 0.92 for precancer, 0.88 for stage 1 cancer and 
0.68 for stage 2 cancer. These values then allow 
the QALYs gained and the cost per QALY 
involved in the treatment of such lesions to be 
calculated.
CONCLUSION
A high quality economic evaluation should 
provide decision makers with information that is 
useful, relevant, and timely. In addition, 
evaluations should be based on rigorous 
analytical methods, be balanced and impartial 
(credible), and be transparent and accessible to 
the reader. 
There are many situations where 
economic evaluations can assist decision makers: 
decisions by various levels of government or 
administrative bodies (e.g., regional health 
authorities, hospitals, drug plans) to fund a 
program, service or technology; pricing 
decisions by government regulators and 
technology manufacturers; clinical practice 
guidelines ; priorities for research funding by 
governments and research-based firms; post-
marketing surveillance and updates of economic 
information based on the use of the technology 
in the “real world” (which can then be used to 
inform one of the other types of decisions).
Economic evaluations can provide 
“value-for money” information to those making 
decisions about the allocation of limited health 
care resources. In particular, economic 
evaluations can be used to identify interventions 
that are worth providing and those that are not. 
Furthermore, evaluations can be used with other 
approaches to help set priorities, such as 
program-budgeting marginal-analysis.
Evaluations do not assess all the 
economic implications of a technology, in 
particular, the financial consequences of 
decisions. Budget impact analysis provides 
complementary information on budgetary 
expenditure and affordability issues. Although 
some data requirements and analytical methods 
are common to both types of analyses, there are 
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key differences between the two, including the 
decision maker question that they address.
Economic evaluations generally do 
not distinguish between financial costs and 
economic (opportunity) costs, which can differ in 
some situations. Consequently, a reference to 
“cost savings” in evaluations generally indicates 
the value of resources freed up (e.g., release of 
hospital beds), which may not translate into 
actual financial savings.
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